東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Serious adverse events following tre...

Sloan, Michael Allan.

Linked to FindBook

Google Book

Amazon

博客來

Serious adverse events following treatment with ticlopidine and aspirin in the African-American Antiplatelet Stroke Prevention Study (AAASPS).

Record Type:	Electronic resources : Monograph/item
Title/Author:	Serious adverse events following treatment with ticlopidine and aspirin in the African-American Antiplatelet Stroke Prevention Study (AAASPS)./
Author:	Sloan, Michael Allan.
Description:	56 p.
Notes:	Source: Masters Abstracts International, Volume: 42-03, page: 0914.
Contained By:	Masters Abstracts International42-03.
Subject:	Health Sciences, Medicine and Surgery. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1416625
ISBN:	0496214107

Serious adverse events following treatment with ticlopidine and aspirin in the African-American Antiplatelet Stroke Prevention Study (AAASPS).
Sloan, Michael Allan.

Serious adverse events following treatment with ticlopidine and aspirin in the African-American Antiplatelet Stroke Prevention Study (AAASPS). - 56 p.

Source: Masters Abstracts International, Volume: 42-03, page: 0914.

Thesis (M.S.)--Rush University, 2003.

Objective. To determine the safety of aspirin and ticlopidine therapy in a clinical trial of recurrent stroke prevention in black patients. Study Design. A randomized, double-blind, investigator-initiated, multicenter trial of 1809 African-Americans with noncardioembolic stroke, with 902 patients receiving ticlopidine 250mg BID and 907 receiving aspirin 325mg BID. We determined the frequencies of adverse events and serious adverse events in an intention-to-treat analysis. Results. Any adverse event occurred in 696 (77%) aspirin treated patients and 715 (79%) ticlopidine treated patients, with only diarrhea being significantly more common in the ticlopidine group (8% vs. 4%, p < 0.0001). Overall, serious adverse events occurred in 28.9% of aspirin treated patients and 29.9% of ticlopidine treated patients (OR = 0.95, 95%Cl = 0.78--1.16, p = 0.63). Overall, there was no difference in the timing of serious adverse events between the groups. Conclusions. There was no difference in the occurrence and timing of serious adverse events between the ticlopidine and aspirin groups. The frequency of adverse events and serious adverse events in this study were high, for unknown reasons.

ISBN: 0496214107Subjects--Topical Terms:

1017756
Health Sciences, Medicine and Surgery.

Serious adverse events following treatment with ticlopidine and aspirin in the African-American Antiplatelet Stroke Prevention Study (AAASPS).
LDR:02116nmm 2200277 4500 001 1837112
005 20050404071508.5
008 130614s2003 eng d
020 $a 0496214107
035 $a (UnM)AAI1416625
035 $a AAI1416625
040 $a UnM $c UnM
100 1 $a Sloan, Michael Allan. $3 1925573
245 1 0 $a Serious adverse events following treatment with ticlopidine and aspirin in the African-American Antiplatelet Stroke Prevention Study (AAASPS).
300 $a 56 p.
500 $a Source: Masters Abstracts International, Volume: 42-03, page: 0914.
500 $a Director: Dilip K. Pandey.
502 $a Thesis (M.S.)--Rush University, 2003.
520 $a Objective. To determine the safety of aspirin and ticlopidine therapy in a clinical trial of recurrent stroke prevention in black patients. Study Design. A randomized, double-blind, investigator-initiated, multicenter trial of 1809 African-Americans with noncardioembolic stroke, with 902 patients receiving ticlopidine 250mg BID and 907 receiving aspirin 325mg BID. We determined the frequencies of adverse events and serious adverse events in an intention-to-treat analysis. Results. Any adverse event occurred in 696 (77%) aspirin treated patients and 715 (79%) ticlopidine treated patients, with only diarrhea being significantly more common in the ticlopidine group (8% vs. 4%, p < 0.0001). Overall, serious adverse events occurred in 28.9% of aspirin treated patients and 29.9% of ticlopidine treated patients (OR = 0.95, 95%Cl = 0.78--1.16, p = 0.63). Overall, there was no difference in the timing of serious adverse events between the groups. Conclusions. There was no difference in the occurrence and timing of serious adverse events between the ticlopidine and aspirin groups. The frequency of adverse events and serious adverse events in this study were high, for unknown reasons.
590 $a School code: 0821.
650 4 $a Health Sciences, Medicine and Surgery. $3 1017756
650 4 $a Black Studies. $3 1017673
690 $a 0564
690 $a 0325
710 2 0 $a Rush University. $3 1261752
773 0 $t Masters Abstracts International $g 42-03.
790 1 0 $a Pandey, Dilip K., $e advisor
790 $a 0821
791 $a M.S.
792 $a 2003
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1416625